A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.
Mult Scler Relat Disord
; 47: 102619, 2021 Jan.
Article
in En
| MEDLINE
| ID: mdl-33189019
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
Multiple Sclerosis
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Mult Scler Relat Disord
Year:
2021
Document type:
Article
Affiliation country:
United States
Country of publication:
Netherlands